– UK, London / SWITZERLAND, Geneva – Advanced Oncotherapy Plc (AIM: AVO), the developer of the next generation of proton-particle therapy for treating cancer, announces that it will appoint Nicolas Serandour as Global Head of Finance and as an Executive Director, effective September 1st. Graham Pughe, who will continue with the Company as Vice President of Finance and Chief Accounting Officer, will report to Nicolas.
Nicolas has over 15 years of experience in the investment banking industry, having worked at JP Morgan, Lehman Brothers and Lazard, where he was most recently responsible for coordinating the European Healthcare sector coverage. He has extensive experience providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies internationally. His transaction experience covers a wide range of private and public strategic transactions, including acquisitions, divestitures, complex alliances and funding of growth companies.
Sanjeev Pandya, CEO of Advanced Oncotherapy commented: “We are delighted to welcome Nicolas on board as Global Head of Finance. We look forward to working together with him and profiting from his enormous know-how and industry experience. Our current priority is execution and creating value. Nicolas knows the healthcare industry well. He brings with him a great combination of finance, capital allocation, value-based planning and strategy skills – critically needed skills as we execute our strategy and deliver long-term value to our shareholders and focus on excellence in execution.”
Commenting on his appointment Nicolas Serandour said: “I am looking forward to working with Sanjeev and the team to deliver Advanced Oncotherapy’s exciting growth strategy. It is a tremendous opportunity to join a company that is at the forefront of the development of proton-therapy systems. I look forward to working with the team to build on its successes and deliver on the opportunities in this next stage of its evolution.”
About Advanced Oncotherapy Plc
Advanced Oncotherapy’s team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.